Yartemlea Injection
NDC Package 62225-300-00
Package Information
Yartemlea (narsoplimab) injection is yARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This formulation utilizes a injection delivery system. Marketed by Omeros Corporation, this product is identified by NDC 62225-300 and is authorized under FDA application BLA761152.
Identification & Billing
- RxCUI: 2732298 - narsoplimab-wuug 370 MG in 2 ML Injection
- RxCUI: 2732298 - 2 ML narsoplimab-wuug 185 MG/ML Injection
- RxCUI: 2732298 - narsoplimab-wuug 370 MG per 2 ML Injection
- RxCUI: 2732305 - YARTEMLEA 370 MG in 2 ML Injection
- RxCUI: 2732305 - 2 ML narsoplimab-wuug 185 MG/ML Injection [Yartemlea]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62225 - Omeros Corporation
- 62225-300 - Yartemlea
- 62225-300-00 - 1 VIAL in 1 CARTON / 2 mL in 1 VIAL
- 62225-300 - Yartemlea
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62225-300-00 identifies a specific commercial package of 1 vial in 1 carton / 2 ml in 1 vial of Yartemlea, a human prescription drug labeled by Omeros Corporation. This injection is formulated for intravenous use and contains narsoplimab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Omeros Corporation on January 20, 2026. The current certification is valid through December 31, 2027.
How is this Omeros Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62225030000. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
